866-997-4948(US-Canada Toll Free)

Dry Eye Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025

Published By :

Transparency Market Research

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 201 Pages

Global Dry Eye Disease Market: Overview

Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. Tears made up of three layers viz. lipids, mucin and aqueous keep eye moist and lubricated. Lack of tears lead to redness, burning, sensing and pain in eye. Dry eye disease also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have prevalence of 8% to 34% across the globe. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye disease. Dry eye is a multifactorial disease, most of the currently approved prescription and currently approved dry eye treatment products are targeted to relief the signs and symptoms of dry eye disease. The choice of treatment depends upon the type and severity of dry eye disease.

Global Dry Eye Disease Market: Scope of the Study

This report on the dry eye disease market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.

Market related factors such as technological developments, product innovation, expansion of healthcare infrastructure facilities around the world, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the dry eye disease market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Dry Eye Disease Market: Key Segments

On the basis of products, the dry eye disease market is categorized into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogue and others. The anti-inflammatory drugs segment is further classified into cyclosporine, corticosteroids and lifitegrast. While the others segment include oral omega supplements, oral tetracycline and eye inserts. On the basis of distribution channel, the dry eye disease market is categorized into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Global Dry Eye Disease Market: Regional Outlook

On the basis of geography, the dry eye disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America comprises the U.S. and Canada. Europe comprises Germany, France, U.K., Spain, Italy and Rest of Europe. Asia-Pacific comprises China, India, Japan, Australia & New Zealand and Rest of Asia Pacific. Latin America comprises Brazil, Mexico and Rest of Latin America.  Middle East & Africa comprises of GCC Countries, South Africa and Rest of Middle East & Africa.

Global Dry Eye Disease Market: Competitive Outlook

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the dry eye disease market. The report also profiles major players in the dry eye disease market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and  FCI S.A.S.

The global dry eye disease market has been segmented as follows:           

Global Dry Eye Disease Market, by Product

  • Artificial Tears
  • Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Punctal Plugs
  • Secretagogue
  • Others

Global Dry Eye Disease Market, by Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies

Global Dry Eye Disease Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of MEA

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Dye Eye Disease Market

4. Market Overview
4.1. Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. High prevalence and rise in incidence rates of dry eye disease and associated risk factors
4.3.1.2. Technical advancements and promising pipeline products
4.3.1.3. Novel dry eye diagnostic tools in offering
4.3.1.4. Growing number of eye care centers prompting surge in product utilization
4.3.2. Restraints
4.3.2.1. High cost of specialty dry eye products with Unclear Reimbursement Scenario
4.3.2.2. Alternative therapies in offering
4.3.3. Opportunities
4.3.3.1. Development of novel treatments
4.4. Global Dye Eye Disease Market Analysis and Forecasts, 2015–2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7.Global Prevalence of Dry Eye Disease
4.8.Pipeline Analysis : Dry Eye Disease Drugs
4.9.Autologous Serum Tears – Overview
4.10.Key Industry Trends

5. Global Dye Eye Disease Market Analysis and Forecasts, By Product 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market value Forecast By Product, 2015–2025
5.4.1. Artificial Tears
5.4.2. Anti-inflammatory
5.4.2.1. Cyclosporine 
5.4.2.2. Corticosteroid
5.4.2.3. Lifitegrast
5.4.3. Punctal Plugs
5.4.4. Secretagogue
5.4.5. Others
5.5. Market Attractiveness By Product 

6. Global Dye Eye Disease Market Analysis and Forecasts, By Distribution Channel 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market value Forecast By Distribution Channel, 2015–2025
6.4.1. Hospital Pharmacies
6.4.2. Independent Pharmacies & Drug Stores
6.4.3. Online Pharmacies
6.5. Market Attractiveness By Distribution Channel 

7. Global Dye Eye Disease Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Market value Forecast By Region
7.2.1. North America 
7.2.2. Europe 
7.2.3. Asia Pacific 
7.2.4. Latin America 
7.2.5. Middle East & Africa 
7.3. Market Attractiveness By Region
7.4. Key Trends, By Region

8. North America Dye Eye Disease Market Analysis and Forecast
8.1. Key Findings
8.2. Market value Forecast By Product, 2015–2025
8.2.1. Artificial Tears
8.2.2. Anti-inflammatory
8.2.2.1. Cyclosporine 
8.2.2.2. Corticosteroid
8.2.2.3. Lifitegrast
8.2.3. Punctal Plugs
8.2.4. Secretagogue
8.2.5. Others
8.3. Market value Forecast By Distribution Channel, 2015–2025
8.3.1. Hospital Pharmacies
8.3.2. Independent Pharmacies & Drug Stores
8.3.3. Online Pharmacies
8.4. Market value Forecast By Country, 2015–2025
8.4.1. US
8.4.2. Canada
8.5. Market Attractiveness Analysis 
8.5.1. By Product 
8.5.2. By Distribution Channel 
8.5.3. By Country

9. Europe Dye Eye Disease Market Analysis and Forecast
9.1. Key Findings
9.2. Market value Forecast By Product, 2015–2025
9.2.1. Artificial Tears
9.2.2. Anti-inflammatory
9.2.2.1. Cyclosporine 
9.2.2.2. Corticosteroid
9.2.2.3. Lifitegrast
9.2.3. Punctal Plugs
9.2.4. Secretagogue
9.2.5. Others
9.3. Market value Forecast By Distribution Channel, 2015–2025
9.3.1. Hospital Pharmacies
9.3.2. Independent Pharmacies & Drug Stores
9.3.3. Online Pharmacies
9.4. Market value Forecast By Country / Sub-region, 2015–2025
9.4.1. Germany
9.4.2. UK
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis 
9.5.1. By Product 
9.5.2. By Distribution Channel 
9.5.3. By Country / Sub-region

10. Asia Pacific Dye Eye Disease Market Analysis and Forecast
10.1.Key Findings
10.2.Market value Forecast By Product, 2015–2025
10.2.1. Artificial Tears
10.2.2. Anti-inflammatory
10.2.2.1. Cyclosporine 
10.2.2.2. Corticosteroid
10.2.2.3. Lifitegrast
10.2.3. Punctal Plugs
10.2.4. Secretagogue
10.2.5. Others
10.3.Market value Forecast By Distribution Channel, 2015–2025
10.3.1. Hospital Pharmacies
10.3.2. Independent Pharmacies & Drug Stores
10.3.3. Online Pharmacies
10.4.Market value Forecast By Country / Sub-region, 2015–2025
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia and New Zealand
10.4.5. Rest of APAC
10.5.Market Attractiveness Analysis 
10.5.1. By Product 
10.5.2. By Distribution Channel 
10.5.3. By Country / Sub-region

11. Latin America Dye Eye Disease Market Analysis and Forecast
11.1.Key Findings
11.2.Market value Forecast By Product, 2015–2025
11.2.1. Artificial Tears
11.2.2. Anti-inflammatory
11.2.2.1. Cyclosporine 
11.2.2.2. Corticosteroid
11.2.2.3. Lifitegrast
11.2.3.Punctal Plugs
11.2.4. Secretagogue
11.2.5. Others
11.3.Market value Forecast By Distribution Channel, 2015–2025
11.3.1. Hospital Pharmacies
11.3.2. Independent Pharmacies & Drug Stores
11.3.3. Online Pharmacies
11.4.Market value Forecast By Country / Sub-region, 2015–2025
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5.Market Attractiveness Analysis 
11.5.1. By Product 
11.5.2. By Distribution Channel 
11.5.3. By Country / Sub-region

12. Middle East & Africa Dye Eye Disease Market Analysis and Forecast
12.1.Key Findings
12.2.Market value Forecast By Product, 2015–2025
12.2.1. Artificial Tears
12.2.2. Anti-inflammatory
12.2.2.1. Cyclosporine 
12.2.2.2. Corticosteroid
12.2.2.3. Lifitegrast
12.2.3. Punctal Plugs
12.2.4. Secretagogue
12.2.5. Others
12.3.Market value Forecast By Distribution Channel, 2015–2025
12.3.1. Hospital Pharmacies
12.3.2. Independent Pharmacies & Drug Stores
12.3.3. Online Pharmacies
12.4.Market value Forecast By Country / Sub-region, 2015–2025
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Israel
12.4.4. Rest of MEA
12.5.Market Attractiveness Analysis 
12.5.1. By Product 
12.5.2. By Distribution Channel 
12.5.3. By Country / Sub-region

13. Competition Landscape
13.1.Market Player – Competition Matrix (By Tier and Size of companies)
13.2.Market Share Analysis By Company (2016)
13.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Santen Pharmaceutical Co., Ltd.
13.3.1.1. Company Overview
13.3.1.2. Business Overview
13.3.1.3. Product Overview
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.1.6. SWOT Analysis
13.3.2. Novartis AG
13.3.2.1. Company Overview
13.3.2.2. Business Overview
13.3.2.3. Product Overview
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.2.6. SWOT Analysis 
13.3.3. Valeant Pharmaceuticals International, Inc. 
13.3.3.1. Company Overview
13.3.3.2. Business Overview
13.3.3.3. Product Overview
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.3.6. SWOT Analysis
13.3.4. Allergan plc 
13.3.4.1. Company Overview
13.3.4.2. Business Overview
13.3.4.3. Product Overview
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.4.6. SWOT Analysis
13.3.5. Shire plc 
13.3.5.1. Company Overview
13.3.5.2. Business Overview
13.3.5.3. Product Overview
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.5.6. SWOT Analysis
13.3.6. TRB Chemedica International SA 
13.3.6.1. Company Overview
13.3.6.2. Business Overview
13.3.6.3. Product Overview
13.3.6.4. Strategic Overview
13.3.6.5. SWOT Analysis
13.3.7. Sun Pharmaceutical Industries Ltd. 
13.3.7.1. Company Overview
13.3.7.2. Business Overview
13.3.7.3. Product Overview
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.7.6. SWOT Analysis
13.3.8. Senju Pharmaceutical Co., Ltd. 
13.3.8.1. Company Overview
13.3.8.2. Business Overview
13.3.8.3. Product Overview
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
13.3.8.6. SWOT Analysis
13.3.9. Sentiss Pharma Pvt. Ltd. 
13.3.9.1. Company Overview
13.3.9.2. Business Overview
13.3.9.3. Product Overview
13.3.9.4. Strategic Overview
13.3.9.5. SWOT Analysis
13.3.10. Johnson & Johnson 
13.3.10.1. Company Overview
13.3.10.2. Business Overview
13.3.10.3. Product Overview
13.3.10.4. Financial Overview
13.3.10.5. Strategic Overview
13.3.10.6. SWOT Analysis
13.3.11. Otsuka Pharmaceutical Co., Ltd. 
13.3.11.1. Company Overview
13.3.11.2. Business Overview
13.3.11.3. Product Overview
13.3.11.4. Financial Overview
13.3.11.5. Strategic Overview
13.3.11.6. SWOT Analysis
13.3.12. Mitotech S.A. 
13.3.12.1. Company Overview
13.3.12.2. Business Overview
13.3.12.3. Product Overview
13.3.12.4. Strategic Overview
13.3.12.5. SWOT Analysis
13.3.13. FCI S.A.S. 
13.3.13.1. Company Overview
13.3.13.2. Business Overview
13.3.13.3. Product Overview
13.3.13.4. Strategic Overview
13.3.13.5. SWOT Analysis

List of Table

Table 01: Pipeline Analysis (1/5)
Table 02: Pipeline Analysis (2/5)
Table 03: Pipeline Analysis (3/5)
Table 04: Pipeline Analysis (4/5)
Table 05: Pipeline Analysis (5/5)
Table 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 07: Global Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 08: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 09: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 11: North America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 12: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 13: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Europe Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 15: Europe Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 16: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 17: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 18: Asia Pacific Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: Asia Pacific Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 20: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 21: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 22: Latin America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 23: Latin America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 24: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 25: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 26: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 27: Middle East & Africa Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
Table 28: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
Table 29: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025

List of Chart

Figure 01: Dry Eye Disease Market Size (US$ Mn), by Product Type, 2016 (A)
Figure 02: Dry Eye Disease Market Revenue (%), by Distribution channel, 2016 (A)
Figure 03: Global Dry Eye Disease Market Revenue (%), by Region, 2016 (A)
Figure 04: Product Type Revenue (%), 2016
Figure 05: Distribution Channel Revenue  (%), 2016
Figure 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, 2015–2025
Figure 07: Market Value Share, by Product Type (2016)
Figure 08: Market Value Share, by Distribution Channel (2016)
Figure 09: Market Value Share, by Region (2016)
Figure 10: Global Prevalence Dry eye Disease
Figure 11: Global Dry Eye Disease Market Value Share, by Product Type, 2016 and 2025
Figure 12: Global Dry Eye Disease Market Attractiveness, by Product Type, 2017–2025
Figure 13: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Tears, 2015–2025
Figure 14: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-inflammatory Drugs, 2015–2025
Figure 15: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Punctal Plugs, 2015–2025
Figure 16: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Secretagogue, 2015–2025
Figure 17: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 18: Global Dry Eye Disease Market Value Share, by Distribution channel, 2016 and 2025
Figure 19: Global Dry Eye Disease Market Attractiveness, by Distribution channel, 2017–2025
Figure 20: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 21: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Drug Stores, 2015–2025
Figure 22: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 23: Global Market Scenario
Figure 24: Global Dry Eye Disease Market Value Share, by Region, 2016 and 2025 
Figure 25: Global Dry Eye Disease Market Attractiveness, by Region, 2017–2025
Figure 26: North America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 27: North America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 28: North America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 29: North America Dry Eye Disease Market Value Share Analysis, by Country, 2016 and 2025
Figure 30: North America Dry Eye Disease Market Attractiveness Analysis, by Country
Figure 31: North America Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 32: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 33: Europe Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 34: Europe Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 35: Europe Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 36: Europe Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 37: Europe Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 38: Europe Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 39: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 40: Asia Pacific Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 41: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 42: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 43: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country  / Sub-region, 2016 and 2025
Figure 44: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 45: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 46: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 47: Latin America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 48: Latin America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 49: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 50: Latin America Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 51: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
Figure 52: Latin America Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 53: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 54: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 55: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
Figure 56: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 57: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 58: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
Figure 59: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Product Type
Figure 60: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
Figure 61: Global Dry Eye Disease Market Share Analysis, by Company (2016)
Figure 62: Santen Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 63: Santen Pharmaceutical Co., Ltd. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 64: Santen Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
Figure 65: Novartis AG.  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 66: Novartis AG. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 67: Novartis AG. Breakdown of Net Sales, By Region, 2016
Figure 68: Valeant Pharmaceuticals International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Valeant Pharmaceuticals International, Inc. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2014–2016
Figure 70: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, By Business Segment, 2016
Figure 71: Allergan plc  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 72: Allergan plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 73: Allergan plc Breakdown of Net Sales, By Business Segment, 2016
Figure 74: Shire plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 75: Shire plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 76: Shire plc Breakdown of Net Sales, By Business Segment, 2016
Figure 77: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 78: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 79: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, By  Region, 2016
Figure 80: Senju Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 81: Senju Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
Figure 82: Johnson & Johnson  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 83: Johnson & Johnson R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 84: Johnson & Johnson Breakdown of Net Sales, By Business Segment, 2016
Figure 85: Otsuka Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 86: Otsuka Pharmaceutical Co., Ltd.  R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 87: Otsuka Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *